Journal of the Minneapolis Heart Institute Foundation
|
|
- Marsha Ryan
- 5 years ago
- Views:
Transcription
1 Journal of the Minneapolis Heart Institute Foundation Informs and educates medical professionals about leading cardiovascular research conducted by MHIF and its partners Publishes clinical research, case reports, view points, literature reviews Features topics across spectrum of cardiovascular disease Published 2x year Open access; available in print and digital Submissions always accepted; Instructions for authors on website Increasing the impact and reach of MHIF research! Page 1 of 36
2 MHIF CARDIOLOGY GRAND ROUNDS Title: Transcatheter Valve Therapy (TVT) 2018 Speaker: Paul Sorajja, MD Director, Center for Valve and Structural Heart Disease Minneapolis Heart Institute at Abbott Northwestern Hospital Date: January 22, 2018 Time: 7:00 8:00 AM Location: ANW Education Building, Watson Room OBJECTIVES At the completion of this activity, the participants should be able to: 1. Recall indications for Transcatheter Aortic Valve Replacement (TAVR). 2. Describe outcomes of Transcatheter Mitral Valve Repair (TMVR). 3. Understand innovations in the field of TVT. ACCREDITATION Physician This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Allina Health and Minneapolis Heart Institute Foundation. Allina Health is accredited by the ACCME to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse This activity has been designed to meet the Minnesota Board of Nursing continuing education requirements for 1.0 hours of credit. However, the nurse is responsible for determining whether this activity meets the requirements for acceptable continuing education. DISCLOSURE STATEMENTS Moderator(s)/Speaker(s) Dr. Sorajja has disclosed that he does not have a conflict of interest in making this presentation. Planning Committee Dr. Alex Campbell, Jake Cohen, Jane Fox, Dr. Mario Goessl, Dr. Kevin Harris, Dr. Kasia Hryniewicz, Rebecca Lindberg, Amy McMeans, Dr. Michael Miedema, Dr. JoEllyn Moore, Pamela Morley, Laura Onstot, Dr. Scott Sharkey, and Jolene Bell Makowesky have declared that they do not have any conflicts of interest associated with the planning of this activity. Dr. David Hurrell declares the following relationship Boston Scientific: Chair, Clinical Events Committee. We gratefully acknowledge the following organization for their commercial support for this activity. Otsuka Pharmaceuticals Pfizer PLEASE SAVE A COPY OF THIS FLIER AS YOUR CERTIFICATE OF ATTENDANCE Signature: My signature verifies that I have attended the above stated number of hours of the CME activity. Allina Health - Learning & Development Chicago Ave - MR Minneapolis MN Page 2 of 36
3 MHIF 2017 Transcatheter Valve Therapy Why, How, and What s Coming Paul Sorajja, MD Roger L. and Lynn C. Headrick Family Chair Valve Science Center Minneapolis Heart Institute Foundation Abbott Northwestern Hospital Disclosures Abbott Vascular: research, consulting, speaking Boston Scientific: research, consulting, speaking Edwards Lifesciences: research, consulting, speaking Admedus: consulting Medtronic: research, consulting, speaking Page 3 of 36
4 WHY WHY = long-term success Smaller Footprint is Desirable Page 4 of 36
5 Invasive Medicine Patients in need Only 1 in 3 treated Iung B et al., EHJ 2005 Bach DS et al., Circ CV Qual Out 2009 Page 5 of 36
6 Commercial TAVR in 2018 Sapien S3 Evolut R Pro Tri-leaflet AS that is not low risk 14 to 18 Fr transfemoral Procedural mortality = 1% Pacemaker = 10 to 15% TAVR Approaches Conscious Sedation Transcarotid Transcaval Balloon Valve Fracturing 0.5 mg midazolam 50 mcg fentanyl $$ millions saved Page 6 of 36
7 Essential Frailty Toolkit EFT 3 potential futility Afilalo J, et al. J Am Coll Cardiol 2017;70(6): Low-risk TAVR Trials PARTNER 3 Sapien 3 Medtronic Evolut Key inclusion Primary outcome Age >65 Symptomatic PROM <2% 1-yr death, CVA, re-hospitalization Any age Symptomatic or Asymptomatic PROM <3% 2-yr death or CVA Follow-up Annual for 10 years Annual for 10 years Page 7 of 36
8 Boston Scientific TAVR Lotus Edge Acurate Neo Minneapolis Heart Institute Treated Patients with Severe Aortic Stenosis 1200 Total no. patients AVR % 38% 41% 37% Page 8 of 36
9 Contemporary Patient Needs 366 appropriate AVR candidates 40% low surgical risk 54% no AVR referral 89% no heart team evaluation One-year outcomes 19% hospitalization for heart failure 55% death Tang L, et al. ACC 2018 Mitral Regurgitation Page 9 of 36
10 Prevalence of Mitral Regurgitation Increases with Age Prevalence (%) of moderate to severe valve disease All valve disease Mitral valve disease Aortic valve disease < >75 Age (years) > 9.3% for 75 year olds Nkomo et al. Burden of Valvular Heart Diseases: A Population-based Study, Lancet, 2006; 368: Survival with Mitral Regurgitation Primary MR Secondary MR Survival (%) ERO <20mm 2 (91 ±3%) ERO 20-39mm 2 (66 ±6%) ERO 40mm 2 (58 ±9%) Survival (%) MI w/o MR 61 ±6 MI with MR 38 ±5 0 P< P< Years Years Enriquez-Sarano M et al. NEJM 2005;352: Grigioni F, et al. Circulation 2001;103: Page 10 of 36
11 Transcatheter Mitral Repair MitraClip >55,000 pts worldwide U.S. approval in 2013 Page 11 of 36
12 Outcomes with MitraClip STS/ACC TVT Registry 100% MR grade % 2 93% 2,952 patients Median age = 82 years STS-PROM (MVR) = 9.2% 60% 40% 4 1/0 61% 20% 0% 3 2 Baseline Post-implant Sorajja P, et al., J Am Coll Cardiol 2017 Clinical Outcomes STS/ACC TVT Registry In-hospital mortality 2.7% Procedure success. 91.8% SLDA % Length-of-stay... 2 d (1,5 d) Home discharge % Sorajja P, et al., J Am Coll Cardiol 2017 Page 12 of 36
13 Challenging Anatomy MitraClip Anatomical Observations Mitraclip in STS/ACC TVT Registry Prior surgical repair. 1.5% FMR.. MVA < 4 cm % 20.5% Gradient 5 mmhg 17.7% Leaflet Ca % Sorajja P, et al., ACC 2017 Page 13 of 36
14 MitraClip Clinical Outcomes at One-Year 40% 35% TVT Registry for MitraClip Either: 37.9% Cumulative incidence (%) 30% 25% 20% 15% 10% 5% Death: 25.9% HF hospitalization: 20.2% Repeat Mitraclip = 6.2% MV surgery = 2.1% 0% Follow-up (months) No. at risk Page 14 of 36
15 Many Developing Repair Options Remaining Challenges Unaddressed MR 100 No MR Recurrence 1,218 surgical pts 15 year FU 13% MR 2 Overall Survival (%) 76 ±1% 80 MR Recurrence 57 ±2% ±5% ±6% 20 HR: 2.06 ( ); p < *HR: P< ( ); p = Follow-up (Years) Suri R et al., J Am Coll Cardiol 2016 Page 15 of 36
16 Post-Procedural MR and Survival TVT Registry for MitraClip 50% 48.9% Cumulative incidence of death 40% 30% 20% 10% Grade III/IV Grade II Grade I or none p< % No. at risk Follow-up (months) III/IV II /I % 21.7% A Procedure of Millimeters Lateral move Page 16 of 36
17 MitraClip and Mitral Surgery Minneapolis Heart Institute (n=604) 140 Annual volumes MitraClip All mitral surgery Isolated MV surgery Procedural mortality <2% for all Niikura H, et al. ACC 2018 Transcatheter Mitral Valves Page 17 of 36
18 First Transcatheter TMVR in U.S. April 8, 2015 The Tendyne Valve Transapical, 34 Fr D-shaped Outer and inner frame Anchoring tether with hemostatic pad Retrievable, repositionable Page 18 of 36
19 Tendyne Global Feasibility Study 30 patients STS-PROM: 7.3% No procedural deaths No MR in 26 of day success: 87% Muller DWM, Sorajja P JACC 2017 Page 19 of 36
20 The Intrepid Prosthesis Self-expanding, nitinol valve 43, 46, or 50 mm Houses a 27 mm bovine valve 35 Fr transapical Images courtesy of Drs. Richard Bae and John Lesser Page 20 of 36
21 Intrepid Global Pilot Study 1-Year Survival 79% NYHA I or II MLWHFQ: 56 ±27 vs. 32 ±22 Bapat V and Sorajja P et al. J Am Coll Cardiol year-old woman HF hospitalization Severe MR Minimal morbidity Sorajja P, Goessl M, Bae R, Tindell L, Lesser J, Askew J, Farivar RS JACC Intv 2017 Page 21 of 36
22 Compassionate Use Tendyne Sorajja P, Goessl M, Bae R, Tindell L, Lesser J, Askew J, Farivar RS JACC Intv 2017 Sorajja P, Goessl M, Bae R, Tindell L, Lesser J, Askew J, Farivar RS JACC Intv 2017 Page 22 of 36
23 Tendyne Valve-in-MAC International Early Feasibility Study Principal Investigators Paul Sorajja, MD Vinod Thourani, MD Launch in Q Next Gen Intrepid TMVR Trans-septal Implant alignment, recapture, and 3x speed Enabled by implant design not requiring rotational alignment or need to capture leaflets One implant platform for both TS and TA Page 23 of 36
24 Treatment of Pathophysiology Aortic Stenosis X Surgery Mitral Regurgitation X? Pressure Hypertrophy Curative Volume Hypertrophy Curative? Accucinch Page 24 of 36
25 Tricuspid Regurgitation Impact of Tricuspid Regurgitation Cumulative incidence of death 50% 40% 30% 20% 10% Severe Moderate Mild/none 38.5% 23.5% 23.4% p< % Follow-up (mos) No. at risk Page 25 of 36
26 Tricuspid Surgery Peri-operative Mortality All patients = 8.8% TV replacement = 13.4% Zack CJ, et al., J Am Coll Cardiol 2017 So many options, a few here Page 26 of 36
27 82 year-old woman Page 27 of 36
28 Page 28 of 36
29 MitraClip for TR 64 patients 88% functional TR 22 combined with MV rx 91% with 1 grade reduction Nickenig G, et al., Circulation 2017 Challenges Can t treat if can t see Page 29 of 36
30 Guideline Absence L-sided valve surgery, severe TR (I) L-sided valve surgery, annular dilatation or RHF (IIA) Primary TR refractory to med rx (IIA) L-sided valve surgery with mod TR and PH (IIB) Severe TR and progressive RV enlargement (IIB) No class I indications for isolated TR Lack of Standard Endpoints VARC-II MVARC TVARC? Page 30 of 36
31 What is meaningful? Asymptomatic TRILUMINATE (EU and US) Early Feasibility Study Moderate or severe TR Single-arm therapy with Triclip First 2 patients worldwide treated at MHI U.S. pivotal study planned for 2018 Page 31 of 36
32 The New Generation Active lifestyle Like less invasive Innovative MHIF Valve Science Center A Call to Action Vision A world class research center for valvular heart disease Mission To improve the health of patients with valvular disease through research, education, and innovation Page 32 of 36
33 Establishment of the Valve Science Center OPERATIONS Steering committee creation Complete vision, goals and metrics Establish financial plan Align MHIF and MHI priorities Establish marketing plan Hire Program Director Hire 1 st Implement database sustainable coordinator financial plan Renew scholar funding Apply for AHA, ACC grants Hire 2 nd database coordinator VSC Faculty education seminar Renew scholar Renew scholar Renew scholar funding Renew funding Renew funding Renew internship internship internship program program program VSC Faculty education seminar RESEARCH Begin Valve Scholar program Establish VHD database 10 scientific Determine papers barriers to VHD care Describe economic costs of barriers Underserved population research 30 scientific papers Start internship program Enroll 2,500 patients in VHD database 55 scientific 85 scientific papers papers Enroll 5,000 patients in VHD database 125 scientific papers Enroll 15,000 patients in VHD database INNOVATE FIM triclip therapy SCOUT study ACCUCINCH EFS Evolut LR top Begin Valve 5 enrollment Scholar program Complete valvein-mac compassionate study Operationalize live case courses Partner with Allina for novel pathway tools Serve as training site for feasibility research Multiple VSC faculty presentations at int l meetings Implement novel pathway tools Host KOL summit Lead multicenter study as national P.I. Host KOL summit Host KOL summit EDUCATE Capture >10 patient testimonials Major website revision Establish social media presence Complete patient education materials Public Seminar Capture >50 Public Seminar Public Seminar Public Seminar Public Seminar patient Valvular Heart Valvular Heart Valvular Heart Valvular Heart testimonials Disease Disease Disease Disease Summit Summit Summit Summit 1 st radio PSA 2nd radio PSA 3rd radio PSA 4th radio PSA 5th radio PSA Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q Patient awareness Page 33 of 36
34 Valentine s Day 5K Register Now: Page 34 of 36
35 Thank you! Durability PARTNER 5-yr Follow-Up HR [95% CI] = 1.04 [0.86, 1.24] p (log rank) = % 62.4% No. at Risk TAVR SAVR Page 35 of 36
36 Medtronic CoreValve US Pivotal High Risk Study ACC 2016 Page 36 of 36
CARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Mitral Disease Speakers: Robert S. Farivar, MD, PhD Chief, Cardiothoracic Surgery, Abbott Northwestern Hospital Chairman, Allina Cardiothoracic; Minneapolis Heart
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Valvular Heart Disease at the Minneapolis Heart Institute: Practice and Innovation Speaker: Robert S. Farivar, MD, PhD Chief, Cardiothoracic Surgery, Abbott Northwestern
More informationEnrolling Interventional Studies
Enrolling Interventional Studies RADIANCE HTN - PI: Yale Wang, MD Patients with essential hypertension being treated 2 antihypertensive medications; treatment resistant hypertension being treated with
More informationOutcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationMitral Regurgitation
Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationPROMINENT. OPEN AND ENROLLING: Please Refer Patients! MHIF FEATURED STUDY:
MHIF FEATURED STUDY: PROMINENT OPEN AND ENROLLING: Please Refer Patients! CONDITION: High triglycerides, low HDL, T2DM, secondary cardiovascular prevention DESCRIPTION: Placebo controlled trial of a potent
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationEmerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX
Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX Conflict of Interest Disclosure Abbott Vascular- Co PI COAPT Trial Medtronic- Executive Committee
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA Mitral Valve Disease Today Mitral regurgitation is the most
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Speakers: Percutaneous Repair of Paravalvular Prosthetic Regurgitation Paul Sorajja, MD Director of the Center for Valve and Structural Heart Disease Minneapolis Heart
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationTranscatheter Mitral Valve for fmr: The Era of Too Many Options
Transcatheter Mitral Valve for fmr: The Era of Too Many Options Isaac George, M.D. Surgical Director, Structural Heart & Valve Center Assistant Professor of Surgery Columbia University Medical Center Disclosure
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationOutcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Fractional flow reserve (FFR) Computed tomography (CT) Speaker: John R. Lesser, MD Senior Consulting Cardiologist, Medical Director CT/CMR Minneapolis Heart Institute at
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationTAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion
TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion Moderator: Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Date: Location: Speaker: ACC 2015 PREVIEW Monday, March 9, 2015, 7:00 8:00 AM ANW Education Building, Watson Room Elevated Troponin in Patients Presenting to the Emergency
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationCARDIOLOGY GRAND ROUNDS
Presentation: Speakers: Presentation: Speakers: Presentation: Speakers: CARDIOLOGY GRAND ROUNDS Date: Case Review: Open thoracoabdominal aortic aneurysm repair Timothy M. Sullivan, MD, Minneapolis Heart
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationVinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
More informationTRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS, MD St Vincent s Hospital, Sydney On behalf of the Tendyne
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationCRITERIA LIST/ QUALIFICATIONS:
CONCERT-HF CONDITION: Ischemic Cardiomyopathy PI: Jay Traverse, MD CONTACT INFO: Jane Fox jane.fox@allina.com ph: 612-863-6289 DESCRIPTION: Phase II, randomized, placebo-controlled clinical trial designed
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationMy Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.
My Choice For Percutaneous Mitral Valve Replacement Jose Luis Navia, MD. Disclosure Edwards Lifescienses St. Jude Medical MAQUET NaviGate Consultant, Investigator Consultant, Investigator Consultant, Investigator
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationGet Ready for Percutaneous Mitral Valve Approaches
Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationROADSTER 2. SPONSOR: Silk Road Medical
ROADSTER 2 CONDITION: Carotid artery disease PI: Jessica Titus, MD CONTACT INFO: Jo Anne Goldman JoAnne.Goldman@allina.com 612-863-3793 DESCRIPTION: The study is intended to evaluate real world usage of
More informationMITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male
MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis
More informationMinimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.
Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Acute Coronary Artery Failure Speaker: Alex R. Campbell, MD Cardiologist Minneapolis Heart Institute at Abbott Northwestern Hospital Scott W. Sharkey, MD, FACC Cardiologist
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationCite this article as:
doi: 10.21037/acs.2018.10.01 Cite this article as: Beller JP, Rogers JH, Thourani VH, Ailawadi G. Early clinical results with the Tendyne transcatheter mitral valve replacement system. Ann Cardiothorac
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationUpdate on a Tethered Transapical Device for TMVR Vinay Badhwar, MD
Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute West Virginia
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationTranscatheter Mitral and Tricuspid Therapies
Edwards Lifesciences 2017 Investor Conference Transcatheter Mitral and Tricuspid Therapies Donald E. Bobo, Jr. Corporate Vice President, Strategy & Corporate Development Edwards is Poised to Lead the Transcatheter
More informationPercutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions
Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More information7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Controversies in AF ablation, pros/cons, LT outcomes Speaker: Bruce D. Lindsay Section Head, Clinical Cardiac Electrophysiology, Vice-Chair Cardiology Cleveland Clinic Date:
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationTranscatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis
Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationPercutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update
Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50
More informationTAVI EN INSUFICIENCIA AORTICA
TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More informationImaging to select patients for Transcatheter TV
Imaging to select patients for Transcatheter TV Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands San Diego, february 2018 Research grants: Medtronic, Biotronik, Boston Scientific,
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationResults of Transfemoral Transcatheter Aortic Valve Implantation
Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More information